Enhancing or eliminating signals for cell survival to treat disease

Area of Science:

• Molecular Biology
• Oncology
• Critical Care Medicine

Background:

• Dysregulation of apoptosis, programmed cell death, contributes to numerous diseases, including cancer and acute injuries.
• Signal transducer and activator of transcription 3 (STAT3) is frequently implicated in cancer's resistance to apoptosis.
• STAT3's role in conditions involving excessive apoptosis, such as hemorrhagic shock, is less understood.

Purpose of the Study:

• To investigate G-quartet oligodeoxynucleotides (GQ-ODNs) as inhibitors of STAT3 DNA binding activity.
• To evaluate the efficacy of GQ-ODNs in inhibiting cancer xenograft growth.
• To determine the therapeutic potential of modulating STAT3 activity in a model of hemorrhagic shock.

Main Methods:

• In vitro assessment of GQ-ODNs' inhibitory effects on STAT3 DNA binding.
• Assessment of GQ-ODN efficacy in inhibiting breast and prostate tumor xenograft growth in nude mice.
• Establishment of a rat model of severe hemorrhagic shock (HS) to study STAT3 activation's effects.

Main Results:

• GQ-ODNs demonstrated potent and selective inhibition of STAT3 DNA binding in vitro.
• GQ-ODNs significantly inhibited the growth of breast and prostate tumor xenografts.
• In HS rats, IL-6-induced STAT3 activation reversed cardiac apoptosis, improved cardiac function, and reduced mortality by fivefold; GQ-ODN pre-treatment blocked these benefits.

Conclusions:

• Targeting STAT3 with inhibitors like GQ-ODNs represents a promising strategy for cancer therapy.
• Activating STAT3 may offer therapeutic benefits in managing acute conditions characterized by excessive apoptosis, such as hemorrhagic shock.
• STAT3 plays a critical role in both cancer progression and the response to severe physiological stress.